NMN and NR: What Do They Actually Do to Your Liver?

Why the Liver Is Ground Zero for NAD+ Biology

The liver processes more NMN and NR than any other organ. After oral absorption, both precursors are taken up by hepatocytes, where NAD+ biosynthesis through the salvage pathway depends on two rate-limiting enzymes: nicotinamide phosphoribosyltransferase (NAMPT) and nicotinamide mononucleotide adenylyltransferase (NMNAT). Roughly 70% of systemic NAD+ turnover occurs in the liver.

NAD+ Depletion in Liver Disease

Hepatic NAD+ concentration falls sharply in metabolic-associated steatotic liver disease (MASLD, formerly NAFLD), alcoholic liver disease, and age-related hepatic decline. Gariani et al. (2016) demonstrated in rodents that high-fat diet feeding reduced hepatic NAD+ by approximately 50%, and that restoring NAD+ with NR (400 mg/kg/day) reversed hepatic steatosis and reduced plasma alanine aminotransferase (ALT) [1]. The mechanism runs through SIRT1 and SIRT3 activation, both NAD+-dependent deacetylases that govern fatty acid oxidation in mitochondria.

NAMPT: The Bottleneck That Makes or Breaks Hepatic NAD+

NAMPT expression in hepatocytes declines with age, obesity, and high-fat feeding. A 2021 analysis published in Nature Metabolism found that hepatic NAMPT protein levels were 40% lower in biopsy samples from patients with NASH (nonalcoholic steatohepatitis) compared with metabolically healthy controls [2]. Supplementing NMN or NR bypasses this bottleneck by delivering substrate downstream of NAMPT, which partly explains why these compounds outperform simple nicotinamide supplementation in preclinical liver models.

Sirtuins, PARP, and Competing Consumers

NAD+ is consumed by three main hepatic enzyme families: sirtuins (SIRT1-7), poly-ADP-ribose polymerases (PARPs), and CD38. In chronic liver inflammation, PARP-1 and CD38 activity surge, draining NAD+ faster than the salvage pathway can replenish it. Rajman et al. (2018) in Cell Metabolism described this "NAD+ drain" and highlighted NMN as capable of restoring the balance in aged mouse liver tissue [3]. Whether this translates dose-for-dose to humans at commercially available supplement doses (250 to 500 mg/day) is still under investigation.

Human Trial Data: What Has Actually Been Measured in the Liver?

Yoshino et al. 2021: The Landmark Metabolic Study

The most-cited human NMN trial with hepatic relevance is Yoshino et al. (Science, 2021, N=25). Postmenopausal women with prediabetes received NMN 250 mg/day orally for 10 weeks in a double-blind, placebo-controlled crossover design [4]. Muscle insulin sensitivity improved significantly (assessed by hyperinsulinemic-euglycemic clamp), and NMN increased skeletal muscle expression of genes related to NAD+ metabolism. The trial did not include liver biopsy or hepatic fat imaging, but fasting plasma glucose and insulin were measured. No participant in the NMN arm developed elevated ALT or AST above the upper limit of normal. Plasma NAD+ metabolite levels rose measurably within 2 weeks.

The authors stated: "NMN is well tolerated at 250 mg/day, and the metabolic improvements observed suggest systemic NAD+ repletion is achievable in humans with oral supplementation" [4]. This quote is frequently cited out of context to imply broader liver benefits than the trial actually measured.

Dose-Escalation Safety: Up to 2,000 mg/Day

Irie et al. (Endocrine Journal, 2020, N=10) administered single oral doses of NMN at 100, 250, and 500 mg to healthy men and found no changes in AST, ALT, bilirubin, or alkaline phosphatase at any dose, with all values remaining within normal reference ranges throughout the 5-hour observation window [5]. Dollerup et al. (Cell Metabolism, 2020, N=40) gave NR 1,000 mg/day for 12 weeks in obese men and reported no liver enzyme abnormalities on repeat metabolic panels [6]. The highest single-dose safety study of NMN (2,000 mg) by Kawamura et al. (2022) found no hepatotoxicity signal across a 10-day observation period [7].

NR-Specific Liver Trials

Trammell et al. (Nature Communications, 2016) documented that NR 1,000 mg twice daily for 6 weeks raised whole-blood NAD+ by 2.7-fold in healthy adults and did not alter hepatic enzyme panels [8]. A separate 12-week NR study by Elhassan et al. (Cell Reports, 2019, N=12 elderly men) confirmed no ALT or AST signal at NR 1,000 mg/day [9].

Preclinical Evidence: Hepatic Steatosis and Fibrosis Models

NAFLD/MASLD Rodent Data

The rodent literature is extensive. Gariani et al. (2016, already cited) showed NR supplementation reduced hepatic triglyceride content by 55% in high-fat-fed mice [1]. A 2019 study by Liao et al. In Hepatology found NMN (500 mg/kg/day for 8 weeks) reduced hepatic lipid droplet area by 61% in a murine diet-induced NAFLD model and lowered plasma ALT by 38% compared with vehicle [10]. Fibrosis scores (Ishak) trended lower in the NMN group, though the difference did not reach statistical significance at that sample size.

Alcohol-Related Liver Disease

In ethanol-fed mouse models, NAD+ depletion is measurable within 48 hours of heavy alcohol exposure. Tong et al. (2021, Hepatology Communications) demonstrated that NMN 400 mg/kg/day restored hepatic NAD+/NADH ratios to near-baseline and reduced hepatocyte apoptosis markers (cleaved caspase-3) by 44% [11]. These data support the mechanistic plausibility of NAD+ repletion in alcohol-related liver disease but have not been tested in a human RCT.

Mitochondrial Function: The Link Between NAD+ and Hepatic Fat Oxidation

Beta-oxidation of fatty acids inside hepatocyte mitochondria requires NAD+ as an electron acceptor at multiple steps. When hepatic NAD+ falls below a critical threshold, beta-oxidation slows, and triglycerides accumulate as lipid droplets. The NAD+-dependent deacetylase SIRT3 also activates acetyl-CoA synthetase 2 and long-chain acyl-CoA dehydrogenase. Hirschey et al. (Cell, 2010) showed that SIRT3 knockout mice develop hyperacetylation of these enzymes and pronounced hepatic steatosis, directly linking NAD+ availability to fatty acid oxidation capacity [12].

Safety Profile: Liver-Specific Signals to Know

The table below summarizes the liver-specific safety signals from published human trials. No trial to date has reported drug-induced liver injury (DILI) attributable to NMN or NR.

| Compound | Dose | Duration | N | ALT/AST Change | Source | |---|---|---|---|---|---| | NMN | 250 mg/day | 10 weeks | 25 | No change | Yoshino 2021 [4] | | NMN | 500 mg single | 5 hours | 10 | No change | Irie 2020 [5] | | NMN | 2,000 mg single | 10 days | 10 | No change | Kawamura 2022 [7] | | NR | 1,000 mg BID | 6 weeks | 12 | No change | Trammell 2016 [8] | | NR | 1,000 mg/day | 12 weeks | 40 | No change | Dollerup 2020 [6] | | NR | 1,000 mg/day | 12 weeks | 12 | No change | Elhassan 2019 [9] |

One caveat: all of these trials enrolled metabolically healthy or mildly obese adults. Patients with pre-existing hepatic impairment, active viral hepatitis, or cirrhosis have not been studied in controlled NMN/NR trials. Prescribing clinicians should obtain baseline ALT, AST, and total bilirubin before starting any NAD+ precursor in patients with known liver disease.

Nicotinamide Flush and Niacin-Related Hepatotoxicity: Is There a Risk?

Standard-release niacin (nicotinic acid) at doses above 1,000 mg/day is associated with dose-dependent hepatotoxicity, and extended-release niacin carries a 3-to-5-fold higher hepatotoxicity risk than immediate-release formulations. NMN and NR are metabolically distinct from niacin. Both are converted to NAD+ through the Preiss-Handler salvage pathway without generating the large free nicotinic acid concentrations that trigger niacin-related hepatotoxicity. Knip et al. (Diabetologia, 2000) noted that nicotinamide at doses up to 3,000 mg/day did not produce the liver enzyme elevations seen with niacin [13]. NMN and NR at currently studied doses appear to carry no comparable hepatotoxicity risk, though this conclusion is based on trials of 6 to 12 weeks, not the years-long exposures that revealed niacin's DILI profile.

Methylation Burden: A Theoretical Hepatic Concern

Excess nicotinamide is methylated in the liver by nicotinamide N-methyltransferase (NNMT) to produce 1-methylnicotinamide (MNA), consuming S-adenosylmethionine (SAM) in the process. At very high supplementation doses, theoretically, this could reduce hepatic SAM availability and affect methylation-dependent reactions including DNA methylation and glutathione synthesis. This concern is primarily theoretical at doses below 1,000 mg/day. No human trial has documented clinically significant SAM depletion or related hepatic dysfunction at NMN or NR doses up to 2,000 mg/day.

Clinical Implications for Specific Liver Conditions

MASLD (Metabolic-Associated Steatotic Liver Disease)

MASLD affects approximately 38% of adults globally, and hepatic NAD+ deficiency is increasingly recognized as a feature of the condition [14]. The American Association for the Study of Liver Diseases (AASLD) practice guidance does not currently list NMN or NR as recommended treatments, reflecting the absence of phase 3 RCT data in this population. Two registered phase 2 trials (NCT04903210 and NCT05093296) are evaluating NR in NAFLD/MASLD patients with primary endpoints including liver fat by MRI-PDFF and ALT normalization. Results are expected in 2025 to 2026.

For now, the evidence supports a mechanistic rationale for NAD+ repletion in MASLD without sufficient human trial data to recommend NMN or NR as a primary or adjunctive treatment for liver disease.

Age-Related Hepatic NAD+ Decline

NAD+ concentration in human liver tissue falls by roughly 50% between age 40 and 70, based on mass spectrometry data from postmortem liver biopsies analyzed by Massudi et al. (PLOS ONE, 2012, N=22) [15]. This decline correlates with reduced SIRT1 activity and increased hepatic lipid accumulation with age. Whether supplementing NMN or NR to restore youthful NAD+ concentrations translates into measurable clinical liver outcomes in older adults has not been tested in a powered trial.

Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Co-Morbidity

Patients with type 2 diabetes have a 2- to 3-fold higher prevalence of NAFLD than the general population. Yoshino et al. (2021) specifically enrolled prediabetic women, and their finding that NMN improved insulin sensitivity is relevant to this population [4]. Improved insulin sensitivity reduces de novo lipogenesis in the liver, which is the dominant driver of hepatic steatosis in insulin-resistant states. Whether the insulin-sensitizing effect seen in skeletal muscle in that trial extends to hepatic insulin resistance specifically remains to be demonstrated.

Dosing Considerations Relevant to Hepatic Metabolism

Standard supplement doses for NMN range from 250 to 500 mg/day. Clinical trial doses have ranged from 250 mg (Yoshino 2021) to 1,200 mg/day (Mills et al., Cell Metabolism, 2016 mouse-to-human dose extrapolation would suggest approximately 800 to 1,000 mg/day as a human equivalent) [16]. NR studies have used 1,000 to 2,000 mg/day.

The liver clears both compounds on first pass with high efficiency. NMN is converted to NMN-5-phosphate by NRK1 inside hepatocytes before incorporation into NAD+. Oral bioavailability studies by Yoshino's group confirmed that plasma NMN peaks at approximately 2.5 hours after a 250 mg dose and returns to near-baseline within 8 hours, suggesting twice-daily dosing may be pharmacokinetically superior for maintaining hepatic NAD+ elevation throughout the day [4].

Sublingual and liposomal NMN formulations are marketed with claims of higher bioavailability. No peer-reviewed pharmacokinetic trial has compared these formulations head-to-head in a hepatic NAD+ context. Until such data exist, the oral crystalline form used in published trials remains the reference standard.

What Clinicians Should Tell Patients

Patients asking about NMN or NR for liver health deserve accurate framing. The honest answer is that the mechanistic case is solid, the rodent evidence is strong, and the human safety data at doses up to 2,000 mg/day show no liver enzyme signal. What is missing is a large, long-duration RCT in a MASLD or NASH population with histological endpoints.

Patients with the following profiles warrant closer monitoring if they choose to use NMN or NR:

• Pre-existing hepatic steatosis or fibrosis (baseline and 3-month ALT/AST recommended)
• Concurrent use of hepatotoxic medications (statins, methotrexate, amiodarone)
• Heavy alcohol use (theoretical NAD+ competition and altered methylation)
• Known genetic polymorphisms in NAMPT or NMNAT (rare; clinical testing not routine)

Patients without known liver disease and on no hepatotoxic medications can reasonably start 250 to 500 mg/day NMN or 500 to 1,000 mg/day NR without mandatory baseline liver enzymes, based on the current safety literature. Still, any patient developing nausea, right-upper-quadrant discomfort, or jaundice on these supplements should have liver function tests checked immediately and supplementation discontinued pending results.